Clinical Trial Update: Lisinopril or Coreg CR® in Reducing Side Effects in Women With Breast Cancer Receiving Trastuzumab [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating lisinopril or Coreg CR in reducing cardiac side effects in women with breast cancer receiving trastuzumab; study completed with results…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Cardiac Toxicity

Drugs mentioned

• COREG CR (carvedilol phosphate)
• Lisinopril (Lisinopril)

Snippet

Sponsor: University of South Florida | Conditions: Breast Cancer, Cardiac Toxicity | Phase 2 | Status: COMPLETED | Results posted: 2021-03-30